Recent findings from a 4-year study reveal that TransCon® PTH (palopegteriparatide) exhibits a sustained and effective response in treating adults with hypoparathyroidism. The long-term data, released by TransCon PTH, supports its potential to enhance the quality of life for patients suffering from this rare endocrine disorder, which is characterized by low levels of calcium in the blood. The findings offer promising insights into stabilizing calcium levels, reducing the dependence on standard calcium and active vitamin D treatments, and alleviating symptoms associated with the disease. Patients who participated in the study demonstrated significant improvements in their condition, underscoring the efficacy of TransCon PTH therapy as a transformative option. As a result, this therapy may redefine current treatment paradigms, offering a new life-changing solution for patients and healthcare providers. Such advancements emphasize the importance of continued research and innovation in the field of endocrine disorders.
GlobeNewswireNew data shows a third of GPs lack fully-qualified NHS roles within one year of training completion
September 2, 2026
A recent analysis reveals that approximately one-third of General Practitioners (GPs) in the UK struggle to obtain fully-qualified roles within the NHS a year after